Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

(2014) Orrin Devinsky et al.   EPILEPSIA

A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost–effectiveness in Germany

(2013) Peter Flachenecker   Expert Review of Neurotherapeutics

Evaluation of the safety and tolerability profile of Sativex®: is it reassuring enough?

(2012) Derick Wade   Expert Review of Neurotherapeutics

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis

(2012) Michael G. Serpell et al.   JOURNAL OF NEUROLOGY

MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial

(2012) John Peter Zajicek et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities

(2012) R. G. Pertwee   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Why do cannabinoid receptors have more than one endogenous ligand?

(2012) V. Di Marzo et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Sativex® in multiple sclerosis spasticity: a cost–effectiveness model

(2012) John Slof et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials

(2011) Mary E. Lynch et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine

(2011) Philip Robson   Expert Opinion On Drug Safety

Sativex®(tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data

(2011) Patrick Vermersch   Expert Review of Neurotherapeutics

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)

(2011) W Notcutt et al.   Multiple Sclerosis Journal

The abuse potential of the synthetic cannabinoid nabilone

(2010) Mark A. Ware et al.   ADDICTION

The Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled Trial

(2010) Mark A. Ware et al.   ANESTHESIA AND ANALGESIA

The endocannabinoid system as a target for the treatment of neurodegenerative disease

(2010) Emma L Scotter et al.   BRITISH JOURNAL OF PHARMACOLOGY

Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity

(2010) Matthias Karst et al.   DRUGS

Drug harms in the UK: a multicriteria decision analysis

(2010) David J Nutt et al.   LANCET

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis

(2010) Derick T Wade et al.   Multiple Sclerosis Journal

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

(2010) C. Collin et al.   NEUROLOGICAL RESEARCH

Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain

(2009) Jeremy R. Johnson et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial

(2008) Ronald J Ellis et al.   NEUROPSYCHOPHARMACOLOGY